Difference between revisions of "O-6-methylguanine-DNA methyltransferase"

Jump to navigation Jump to search
no edit summary
Line 1: Line 1:
'''O-6-methylguanine-DNA methyltransferase''' (MGMT) is a gene encoding for O6-alkylguanine DNA alkyltransferase which is required for genomic stability.
'''O-6-methylguanine-DNA methyltransferase''', abbreviated '''MGMT''', is a gene encoding for O6-alkylguanine DNA alkyltransferase which is required for genomic stability.
Because the product can antagonize the efficiacy of alkylating substances, the methylation state of the MGMT gene determines whether tumor cells in [[glioblastoma]] would be responsive to therapy with [[temozolomide]]. A methylated (ie silenced) MGMT promotor is therefore a predictive and prognostic biomarker.<ref>{{Cite journal  | last1 = Stupp | first1 = R. | last2 = Hegi | first2 = ME. | last3 = Mason | first3 = WP. | last4 = van den Bent | first4 = MJ. | last5 = Taphoorn | first5 = MJ. | last6 = Janzer | first6 = RC. | last7 = Ludwin | first7 = SK. | last8 = Allgeier | first8 = A. | last9 = Fisher | first9 = B. | title = Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. | journal = Lancet Oncol | volume = 10 | issue = 5 | pages = 459-66 | month = May | year = 2009 | doi = 10.1016/S1470-2045(09)70025-7 | PMID = 19269895 }}</ref>
Because the product can antagonize the efficiacy of alkylating substances, the methylation state of the MGMT gene determines whether tumor cells in [[glioblastoma]] would be responsive to therapy with [[temozolomide]]. A methylated (ie silenced) MGMT promotor is therefore a predictive and prognostic biomarker.<ref>{{Cite journal  | last1 = Stupp | first1 = R. | last2 = Hegi | first2 = ME. | last3 = Mason | first3 = WP. | last4 = van den Bent | first4 = MJ. | last5 = Taphoorn | first5 = MJ. | last6 = Janzer | first6 = RC. | last7 = Ludwin | first7 = SK. | last8 = Allgeier | first8 = A. | last9 = Fisher | first9 = B. | title = Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. | journal = Lancet Oncol | volume = 10 | issue = 5 | pages = 459-66 | month = May | year = 2009 | doi = 10.1016/S1470-2045(09)70025-7 | PMID = 19269895 }}</ref>


48,470

edits

Navigation menu